CD8A and neoplasm: As tucidinostat plus PD-L1 blockade resulted in tumor regression and flow cytometry profiling revealed enhanced CD8+ T cell infiltration, we hypothesized that the observed antitumor responses were mediated through CD8+ T cell populations.